{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/attention-deficit-hyperactivity-disorder/prescribing-information/methylphenidate/","result":{"pageContext":{"chapter":{"id":"e54ebc77-0347-59b3-9363-2fa71e52a56d","slug":"methylphenidate","fullItemName":"Methylphenidate","depth":2,"htmlHeader":"<!-- begin field ea9cc947-a0c6-46b5-add0-55cc99ac58cf --><h2>Methylphenidate</h2><!-- end field ea9cc947-a0c6-46b5-add0-55cc99ac58cf -->","summary":"","htmlStringContent":"<!-- begin item dfa7547d-0e9b-4997-8acc-72f84d4f3351 --><!-- begin field f387f991-7fc0-47e1-9ac1-184f869cc55f --><ul><li>Methylphenidate is <em>always </em>initiated in secondary care by a specialist. However, treatment may be continued and <a class=\"topic-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/management/management/#managing-confirmed-adhd\">monitored</a> by a general practitioner under a shared-care protocol.</li></ul><!-- end field f387f991-7fc0-47e1-9ac1-184f869cc55f --><!-- end item dfa7547d-0e9b-4997-8acc-72f84d4f3351 -->","topic":{"id":"58fdf356-8ba5-546f-8dc0-2f52caf10b0d","topicId":"634d93f6-99ac-40ea-821e-2886075c4f40","topicName":"Attention deficit hyperactivity disorder","slug":"attention-deficit-hyperactivity-disorder","lastRevised":"Last revised in January 2021","chapters":[{"id":"97f99690-0b45-5db9-91f6-a4ccf1441f55","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3288c19f-08ea-5db5-9fe3-2a19e4e9480e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"117c3288-2c4b-54a9-93a6-e73cfa827ea6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"05022ed2-5af8-5139-9aee-325340958ba7","slug":"changes","fullItemName":"Changes"},{"id":"280f9139-8e61-5232-b633-87792a692c21","slug":"update","fullItemName":"Update"}]},{"id":"7df3faa3-c76c-5513-8300-b8e6c29a6710","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"dd6487fd-840a-583c-9def-1b3fbf119433","slug":"goals","fullItemName":"Goals"},{"id":"7d672b8e-e109-5eee-9f6a-937dc8647595","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6ee4b93a-2830-5f51-9991-1c95ef010724","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f40bd230-c678-561c-9d40-5bc8424b3e61","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"473473fc-1cf7-5675-876d-9cf4806ca71c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b7ed8daa-37ed-5957-8040-2744764b2b9c","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9199d39e-4690-591d-9e22-737af0484d8b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"60a29f8c-bc0e-5bb1-9846-a4ef0725acfb","slug":"definition","fullItemName":"Definition"},{"id":"0e5e3505-ad73-5fe3-889b-d803507818a4","slug":"causes","fullItemName":"Causes"},{"id":"f3cd314a-8d03-53ce-a0c0-924d345fc73e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b286aedf-f99c-5903-9289-953caa385920","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ab5906d5-d2b3-5bc3-bfcf-512c0aa8be1e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d3399591-ed2d-5c77-9855-2e0b917c37ae","slug":"when-to-suspect-adhd","fullItemName":"When to suspect ADHD"},{"id":"79f2001b-57c3-521d-a4b3-a30df47980b7","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"2bfc757a-5a5f-5796-bd7d-b0b48edaa5fc","fullItemName":"Management","slug":"management","subChapters":[{"id":"0042040f-0d1c-5531-856f-e59d3ecbfe9f","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c3622cf7-82a4-5194-ba3d-ee79d5dcc6b1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e54ebc77-0347-59b3-9363-2fa71e52a56d","slug":"methylphenidate","fullItemName":"Methylphenidate"},{"id":"4cb27755-8a20-55e7-abf6-188f7ef4cc15","slug":"atomoxetine","fullItemName":"Atomoxetine"},{"id":"cdfd970d-3454-539a-8119-612214e9ba0c","slug":"amfetamines","fullItemName":"Amfetamines"}]},{"id":"c30641a4-ca7b-5cc3-bd1a-68cb35616b7b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"114d2691-2ead-5200-a465-7a97d6ea302e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"42cd6093-4642-503a-aee2-abe24e0af20c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"ebdae4e0-6a27-5f95-af59-4d19d02719c5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2dc4be40-cd79-5b84-940c-7d3b5ddf196d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b89b6177-f75f-51ac-b701-99a0ce4f254e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5c21ec37-f21e-535e-81a7-d99081cf961e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cdb8e542-54f7-55a2-9ef4-42e064fccfff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c3622cf7-82a4-5194-ba3d-ee79d5dcc6b1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"370c2735-db47-5cc3-ae3f-adfff26de4d6","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 435107df-1edd-4770-be51-08058c75b05b --><h3>What adverse effects are associated with methylphenidate?</h3><!-- end field 435107df-1edd-4770-be51-08058c75b05b -->","summary":"","htmlStringContent":"<!-- begin item bb1b4ff8-d01c-4502-8831-286759afdd8a --><!-- begin field 02b7d4f4-d524-47cf-99a0-2d3e31d18cd5 --><ul><li><strong>The most common adverse effects of methylphenidate include:</strong><ul><li>Gastrointestinal effects such as abdominal pain, nausea, vomiting, diarrhoea, dyspepsia, dry mouth, and anorexia.</li><li>Cardiovascular effects such as tachycardia, palpitation, arrhythmias, and changes in blood pressure.</li><li>Central nervous system effects such as insomnia, nervousness, asthenia, depression, irritability, aggression, headache, drowsiness, dizziness, dysphemia, and movement disorders.<ul><li>Methylphenidate can impair cognitive function and affect the person's ability to drive. People taking methylphenidate should be told that this medicine may affect their ability to drive and they should not drive if they are affected.</li></ul></li><li>Dermatological effects such as pruritus and rash.</li><li>Other adverse effects including reduced weight gain, cough, nasopharyngitis, tics (very rarely Tourette syndrome), fever, arthralgia, alopecia, and growth restriction.</li></ul></li><li><strong>Less common adverse effects include </strong>constipation, dyspnoea, dysphemia, abnormal dreams, confusion, suicidal ideation, urinary frequency, haematuria, muscle cramps, and epistaxis.</li><li><strong>Rarely, </strong>angina, sweating, and visual disturbances have been reported.</li><li><strong>Very rarely, </strong>the following have been reported hepatic dysfunction, myocardial infarction, cerebral arteritis, psychosis, seizures, neuroleptic malignant syndrome, tolerance and dependence, blood disorders including leucopenia and thrombocytopenia, angle-closure glaucoma, exfoliative dermatitis, and erythema multiforme, supraventricular tachycardia, bradycardia, and convulsions.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">ABPI, 2021</a>]</p><!-- end field 02b7d4f4-d524-47cf-99a0-2d3e31d18cd5 --><!-- end item bb1b4ff8-d01c-4502-8831-286759afdd8a -->","subChapters":[]},{"id":"3c76756e-295e-565a-88fe-ca1bc7f311c9","slug":"interactions","fullItemName":"Interactions","depth":3,"htmlHeader":"<!-- begin field dbb38fb8-8684-4183-a271-7ac582e15447 --><h3>What key drug interactions are associated with methylphenidate?</h3><!-- end field dbb38fb8-8684-4183-a271-7ac582e15447 -->","summary":"","htmlStringContent":"<!-- begin item 0151579f-1e7c-48a4-a56c-1326614992b4 --><!-- begin field f7e2969d-f524-48d6-9336-ec22283f0f9a --><p><strong>Key drug interactions with methylphenidate include:</strong></p><ul><li><strong>Anticoagulants </strong>— methylphenidate possibly enhances the effect of anticoagulants (for example warfarin). Dose adjustment of these drugs might be needed when starting methylphenidate.</li><li><strong>Antihypertensives</strong> — methylphenidate may decrease the effectiveness of drugs used to treat hypertension.</li><li><strong>Antipsychotics </strong>— because a predominant action of methylphenidate is to increase extracellular dopamine levels, methylphenidate may be associated with pharmacodynamic interactions when co-administered with direct and indirect dopamine agonists, or with dopamine antagonists including antipsychotics.</li><li><strong>Carbamazepine </strong>— carbamazepine may decrease the levels of methylphenidate and therefore it is advised to monitor the response to methylphenidate.</li><li><strong>Drugs that elevate blood pressure </strong>— caution is advised in people being treated with methylphenidate with other drugs that can also elevate blood pressure.</li><li><strong>Phenytoin </strong>— methylphenidate may rarely increase phenytoin levels and the risk of toxicity.</li><li><strong>Monoamine oxidase inhibitors (MAOIs) </strong>— concurrent use of two or more serotonergic drugs may increase the risk of serotonin syndrome and symptoms similar to neuroleptic malignant syndrome. Additionally, concurrent use of MAOIs and methylphenidate may precipitate a hypertensive crisis. Therefore, do not prescribe an MAOI to a person taking methylphenidate. Be aware that methylphenidate should not be used for at least 14 days after stopping treatment with an MAOI, and treatment with an MAOI should not be initiated within 14 days after stopping methylphenidate. </li><li><strong>Selective serotonin reuptake inhibitors (SSRIs) </strong>— methylphenidate may increase the risk of central nervous system adverse effects of SSRIs. If this becomes troublesome, consider stopping one of the two drugs.</li><li><strong>Tricyclic antidepressants </strong><strong>(TCAs) </strong>— methylphenidate may increase both the effect and adverse effects of TCAs. Monitor for adverse effects of TCAs if concurrent use is indicated and if present, adjust the dose of the TCA as needed.</li><li><strong>Alcohol </strong>— concomitant use of alcohol with methylphenidate enhances the effects of methylphenidate. Advise that alcohol should be avoided whilst taking methylphenidate.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">BNF 75, 2018</a>] </p><!-- end field f7e2969d-f524-48d6-9336-ec22283f0f9a --><!-- end item 0151579f-1e7c-48a4-a56c-1326614992b4 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}